Kornimate/medical-research-clean huggingface dataset:
the efficacy of stellate ganglion block as post-traumatic stress disorder (ptsd) therapy: a pilot study

Conditions: Stress Disorders, Post-Traumatic

Summary: rationale: a stellate ganglion nerve block may help relieve symptoms of post-traumatic stress disorder (ptsd). purpose: this pilot clinical trial is studying the efficacy of a stellate ganglion nerve block in veterans to reduce the symptoms of ptsd in relatively long-standing (vietnam era) induced or relatively recently induced ptsd (from deployment in afghanistan or iraq as part of operations enduring freedom (oef), iraqi freedom (oif), and new dawn (ond).

objectives: 1. stellate ganglion blocks will be performed in a small sample (n = 12) of the local patient population that suffers from ptsd in order to replicate other preliminary findings. 2. the parameters that lead to a successful treatment response will be evaluated by comparing and contrasting the results obtained in younger (n=6) oef/oif generation veterans versus older (n=6) vietnam generation veterans. 3. the individual difference variables that might lead to successful treatment responses will be studied by obtaining correlative measures of psychological and psychometric data and responses to standardized tests. research design: this is an open label unblinded clinical pilot case series study to determine the efficacy of stellate ganglion blockade for relief of ptsd symptoms in the long beach va healthcare population.

Eligibility criteria:
inclusion criteria: * include significant ptsd symptoms with severe hyper-arousal symptoms. * clinician administered ptsd scales (caps) score, with a total score ≥ 50 needed for enrollment. * hyper-arousal severity identified by a high score on the caps d scale and a ≥ 10 beat per minute increase in heart rate during the subject's verbal recollection of a standardized version of their traumatic exposure. exclusion criteria: * include psychiatric and medical conditions that would make patients poor candidates for an outpatient procedure. * subjects must be able to be cooperative for the procedure and free of significant medical problems that would pose a constant threat to life.

Keywords: post-traumatic stress disorder stellate ganglion cervical plexus local anesthesia anxiety
7t mrs in parkinson's disease

Conditions: Parkinson's Disease

Summary: this study is looking for healthy controls and patients with parkinson's (pd) to perform an mr scan. 1. the neurochemical profile of the sn of patients with pd as measured by high field mrs will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and n-acetylaspartate and glutamate will be lower due to neuronal loss/damage. 2. there will be a relationship between neurochemical changes and disease severity.


Eligibility criteria:
inclusion criteria: parkinson's disease group * parkinson's disease (clinical diagnostic criteria) * age 45-75 years inclusive * able to safely undergo mri scanning * absence of diabetes and smoking * capable of giving informed consent healthy control group * age 45-75 years inclusive * able to safely undergo mri scanning * absence of diabetes and smoking * capable of giving informed consent exclusion criteria: parkinson's disease group * dementia (clinically determined by pi dr. tuite) * diagnosis of atypical parkinsonism * inability to safely undergo mri scanning * inability to give informed consent * unstable medical conditions * present smoker * diabetic (on oral or injectable medications for diabetes) * taken coenzyme q10 or vitamin e in the 2 weeks prior to the scan * does not meet age criteria healthy control group * has a 1st degree relative with pd * dementia (clinically determined by pi dr. tuite) * inability to safely undergo mri scanning * inability to give informed consent * unstable medical conditions * present smoker * diabetic (on oral or injectable medications for diabetes) * taken coenzyme q10 or vitamin e in the 2 weeks prior to the scan * does not meet age criteria

Keywords: parkinson's disease pd magnetic resonance spectroscopy
safety study of a shorter (hypofractionated) radiotherapy for the prostate bed with or without the pelvic lymph nodes

Conditions: Prostate Cancer

Summary: this trial investigates safety and feasibility of a hypofractionated radiotherapy (i.e. with higher daily doses and shorter total treatment time compared to standard fractionation) of the prostate bed with or without the pelvic lymph nodes.

while evidence on safety and efficacy of primary hypofractionated radiotherapy in prostate cancer is accumulating, data on postoperative hypofractionated treatment of the prostate bed and of the pelvic lymph nodes is still scarce. this phase ii trial was initiated to investigate safety and feasibility of hypofractionated treatment of the prostate bed alone or with the pelvic lymph nodes. a total of 80 prostate cancer patients with the indication for adjuvant radiotherapy will be enrolled, where 40 patients with a low risk of lymph node involvement (arm 1) and another 40 patients with a high risk of lymph node involvement (arm 2) will each receive 54 gy in 18 fractions to the prostate bed. arm 2 will be given 45 gy to the pelvic lymph nodes additionally. helical tomotherapy and daily image guidance wil be used.

Eligibility criteria:
inclusion criteria: * resected prostate carcinoma with histological grading (gleason score) * status post prostatectomy for a pt3 carcinoma and/or r1/2 resection or psa recurrence after prostatectomy (2 consecutive psa rises) * psa recurrence ≥ 1 ng/ml: ct/pet/mri imaging excluding pathological lymph nodes * karnofksy performance score ≥ 70 % * age 18 - 80 years * only arm 2: antihormonal therapy for 2 months prior to radiotherapy and continuation of hormonal suppression after radiotherapy recommended * written informed consent exclusion criteria: * patient's refusal * patient's inabillity to give informed consent * stage iv (distant metastases) * lymph node involvement outside the pelvis * severe wound complications after laparatomy * only arm 2: severe lymphoedema of the legs, elephantiasis, postthrombotic syndrome * decompensated pulmonary, cardiovascular, metabolic, hematopoetic, coagulatory or renal comorbidities * known other malignant disease with distant metastases * prior pelvic irradiation * participation in another clinical trial that might compromise the results of the priamos trial or the other trial

Keywords: prostatectomy
combined spinal epidural anesthesia and general anesthesia for laparoscopic cholecystectomy

Conditions: Gall Stone Disease; Polyp

Summary: the aim of this study was to compare general anesthesia (ga) and combined (epidural and spinal) anesthesia (ca) for laparoscopic cholecystectomy. general anesthesia is a gold standard for laparoscopic cholecystectomy(lc). the use of combined anesthesia may offer several advantages over general anesthesia. fifty patients will be randomly assigned to either the ca lc (25 patients) or ga lc (25 patients). all patients has symptomatic gall stone disease or polyp of gall bladder. intraoperative events related to combined anesthesia , postoperative complications, pain score and duration of operation time will record.

objective of study : the aim of this study was to compare general anesthesia (ga) and combined (epidural and spinal) anesthesia (ca) for laparoscopic cholecystectomy. general anesthesia is a gold standard for laparoscopic cholecystectomy(lc). the use of combined anesthesia may offer several advantages over general anesthesia. material and methods : fifty patients will be randomly assigned to either the ca lc (25 patients) or ga lc (25 patients). all patients has symptomatic gall stone disease or polyp of gall bladder. intraoperative events related to combined anesthesia : abdominal discomfortable, shoulder pain, abdominal pain, nausea, anxiety, dermatomal level of sensory blockade, respiratory depression. we compare between two group; shoulder pain, postoperative complications, pain score, duration of operation time and length of hospital stay. fifty patients will select prospectively for lc, under low pressure (10 mm hg) pneumoperitoneum and under combined anesthesia and general anesthesia. spinal anaesthesia was performed at l1-l2 interspace using 2 ml of 0.5% (10 mg) hyperbaric bupivacaine mixed with 0.5ml (25 micrograms) of fentanyl. epidural catheter was inserted at l1- l2 interspace too.

Eligibility criteria:
inclusion criteria: * gall stone disease, polyp exclusion criteria: * gall bladder cancer

Keywords: combined anesthesia general anesthesia laparoscopic cholecystectomy
ko-2806 monotherapy and combination therapies in advanced solid tumors

Conditions: Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer)

Summary: this first-in-human (fih) dose-escalation and dose-validation/expansion study will assess ko-2806, a farnesyl transferase inhibitor (fti), as a monotherapy and in combination, in adult patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * histologically or cytologically confirmed advanced solid tumors * arm #1 (monotherapy): hras-mutant and/or amplified tumors (any solid tumor type); hras overexpression (only for hnscc tumors); kras and/or nras, and/or hras-mutant and/or amplified nsclc or crc; kras-mutant and/or amplified pdac * arm #2 (combination): must have received at least 1 prior systemic therapy with io-based treatment for locally advanced or metastatic rcc * arm #3 (combination): must have kras g12c-mutant locally advanced or metastatic nsclc, crc, or pdac and have received at least 1 prior systemic therapy for advanced or metastatic disease * measurable disease by response evaluation criteria in solid tumors (recist) v1.1. * karnofsky performance status of 70 or higher with no clinically significant deterioration over the previous 2 weeks. * acceptable liver, renal, endocrine, and hematologic function. * other protocol-defined inclusion criteria may apply. exclusion criteria: * ongoing treatment with certain anticancer agents. * prior treatment with an fti or hras inhibitor. * major surgery, other than local procedures, within 28 days prior to cycle 1 day 1, without complete recovery. * spinal cord compression, leptomeningeal disease, or clinically active cns metastases. * toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent. * active or prior documented autoimmune or inflammatory disorders within the past 5 years prior to cycle 1 day 1 (with exceptions). * active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. * inability to swallow, impairment of gastrointestinal (gi) function or gi disease that may significantly alter the absorption of the trial drugs. * inadequate cardiac and/or vascular function, including receipt of treatment for unstable angina, myocardial infarction, and/or cerebro-vascular attack within the prior 6 months, mean qtcf ≥470 ms, or class ii or greater congestive heart failure. * other invasive malignancy within 2 years. * other protocol-defined exclusion criteria may apply.

Keywords: hras kras nras farnesyl transferase inhibitor (fti) tyrosine kinase inhibitor (tki) phase 1 kras g12c inhibitor nsclc ccrcc rcc pdac crc
seacare's care coordination for diabetes management in a primary care office

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to determine whether it is possible to improve health outcomes for patients with type ii diabetes, a community-based health care agency will offer care coordination to half of a study group in a family practice office. the intervention will include assessing patients' status using two instruments: a depression screen (the phq9) and a motivation to change scale (the patient activation measure, pam). a masters-level social worker will counsel patients in the intervention group. changes in patients' health status, phq9 scores and pam scores over one year will be measured. outcomes will be compared between the study group and the group without intervention.


Eligibility criteria:
inclusion criteria: * diabetes type ii exclusion criteria: * non-english speaking

Keywords: diabetes
the effect of myofascial release technique on the treatment of primary dysmenorrhea in psoas muscle

Conditions: Woman; Primary Dysmenorrhoea

Summary: dysmenorrhea is a series of pathological symptoms associated with menstruation that interfere with daily activities such as abdominal cramps and pain in the menstrual period. general symptoms such as nausea, vomiting, lumbago, diarrhea and headache are also common. primary dysmenorrhea refers to menstrual pain that does not depend on the underlying pathology. the kidneys act on the fascia of the psoas muscle. if the psoas muscle does not shorten and grow sufficiently, the kidneys may not move for a certain period of time and may experience ptosis. this causes venous ponding and may cause varicocele in men and primary dysmenorrhea in women. techniques to be applied directly to the fascia of the psoas muscle can reduce symptoms of dysmenorrhea in women. in the literature review, no studies investigating the effectiveness of a treatment applied directly and only on the psoas muscle on primary dysmenorrhea were not found. this study can set an example for future studies. in our study, myofascial relaxation technique will be applied in women with primary dysmenorrhoea and its effect on pain will be examined.


Eligibility criteria:
inclusion criteria: * the age range is 18-30, * intense pain compared to visual analog scale in the lower region of the abdomen during or just before the menstruation period (\> 4), * no pregnancy history, * not using drugs for dysmenorrhea symptoms exclusion criteria: * not agreeing to participate in the study, * endometriosis, ovarian cyst, uterine fibroid, congenital malformation or pelvic inflammation, * having a diagnosis of secondary dysmenorrhea
comparative study examining the effectiveness in use of a dermojet and a normal syringe treatment for patients with hair loss - alopecia areata

Conditions: Alopecia Areata

Summary: conventional treatments include the use of steroids applied locally, or injection in to the legion, or oral therapy. treatment is determined by the severity of the disease. injection in to the legion can be done in two methods 1. subcutaneous injection syringe lower 2. using syringe dermojet - a syringe without a needle. so far there are no publications in the medical literature of studies comparing efficacy, safety, convenience of use for doctor-patient, of both methods.


Eligibility criteria:
inclusion criteria: 1. subjects over the age of 18 2. men and women 3. the presence of at least two lesions (centers) in diameter of at least 1.5 cm on both sides of the scalp. 4. healthy with no diseases that constitute the background against the total label use steroids exclusion criteria: 1. pregnant women 2. involvement of more then 50% of the scalp 3. patients with immunodeficiency-related diseases 4. patients receiving systemic steroids
oasis-hae: a study to evaluate the safety and efficacy of donidalorsen (isis 721744 or ionis-pkk-lrx) in participants with hereditary angioedema (hae)

Conditions: Hereditary Angioedema

Summary: the purpose of this study was to evaluate the safety and efficacy of donidalorsen in participants with hae and effect of donidalorsen on the quality and pattern of hae attacks and their impact on quality of life (qol).

this was a phase 3, multi-center, double-blind, randomized, placebo-controlled study of donidalorsen in 91 participants. participants were randomly assigned in a 2:1 ratio to cohort a (donidalorsen or placebo every 4 weeks) or cohort b (donidalorsen or placebo every 8 weeks), respectively. within each cohort, participants were randomized in a 3:1 ratio to receive donidalorsen or matching-placebo. the study included an up to 8-week screening period, a 24-week treatment period, and an up to 13-week post-treatment period.

Eligibility criteria:
key inclusion criteria 1. participants, or their legally appointed and authorized representatives, must provide written and signed informed consent form (icf)/assent 2. participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent 3. participants must have a documented diagnosis of hereditary angioedema type 1 (hae-1)/hereditary angioedema type 2 (hae-2) 4. participants must: 1. experience a minimum of 2 hae attacks (confirmed by the investigator) during the screening period 2. be willing to complete the participant reported outcomes (pro) assessments throughout the study 5. participants must have access to, and the ability to use acute medication(s) to treat angioedema attacks key exclusion criteria 1. concurrent diagnosis of any other type of recurrent angioedema, including acquired, idiopathic angioedema or hae with normal c1-inh (also known as hae type iii) 2. any clinically-significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion in the study 3. treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening 4. participated in a prior isis 721744 study 5. exposure to any of the following medications: 1. angiotensin-converting enzyme (ace) inhibitors or any estrogen containing medications with systemic absorption within 4 weeks prior to screening 2. chronic prophylaxis with takhzyro, haegarda, cinryze and ruconest or orladeyo within 5 half-lives prior to screening 3. oligonucleotides (including small interfering ribonucleic acid \[sirna\]) within 4 months of screening if single dose received, or within 12 months of screening if multiple doses received. this exclusion does not apply to vaccines 6. recent history (3 years) of, or current drug or alcohol abuse

Keywords: hae
an expanded access program of tarceva (erlotinib) in participants with advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: this study will provide treatment with erlotinib to participants with advanced nsclc who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either. efficacy and safety will be monitored throughout the study.


Eligibility criteria:
inclusion criteria: * adults greater than or equal to (≥) 18 years of age * histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent nsclc * previous treatment with no more than 2 prior chemotherapy regimens exclusion criteria: * previous systemic anti-cancer therapy with human epidermal growth factor receptor 1 (her1)/epidermal growth factor receptor (egfr) inhibitors * inability to take oral medication * any other malignancies within 5 years
dynamic cervical implant (dci) versus anterior cervical discectomy and fusion(acdf) for the treatment of single-level cervical degenerative disc disease (ddd): an rct

Conditions: Cervical Degenerative Disc Disease

Summary: to compare the clinical and radiographic outcomes of dci vs acdf for the treatment of single-level cervical degenerative disc disease (ddd)

anterior cervical discectomy and fusion (acdf) is an effective and safe treatment for patients with radiculopathy and myelopathy. however, in the untreated levels adjacent to a fusion, increased motion and elevated intradiscal pressures have been reported. some investigators have postulated that these changes may lead to an increased risk of adjacent segment degeneration (asd). limitations and problems with acdf have led some investigators to explore the motion-preserving surgeries, such as cervical total disk replacement (tdr). although tdr has been shown to reduce adjacent-level intra discal pressures and provide a more physiological overall cervical but also index- and adjacent-level range of motion (rom) while maintaining sagittal alignment. recent studies have also highlighted the potential limitations of tdr. dynamic cervical implant (dci) is a type of anterior decompression and cervical non-fusion implant that was initially conceived as a method to combine the potential advantages of fusion and tdr. the dci is intended to provide controlled, limited flexion and extension-the primary motions in the sub axial cervical spine-that is greater than that seen with fusion, but less than that achieved with tdr .

Eligibility criteria:
inclusion criteria: * single or multiple symptomatic cervical ddd with radiculopathy and\\or mylopathy not responding to non-surgical management * age older than 18 years exclusion criteria: 1. ossification of posterior longitudinal ligament 2. facet arthritis 3. lack of motion or instability at the level of surgery 4. fracture 5. infection 6. tumors 7. osteoprosis

Keywords: cervical degenerative disc disease dynamic cervical implant anterior cervical discectomy and fusion
effect of milnacipran / gabapentin in fibromyalgia

Conditions: Fibromyalgia

Summary: gabapentin and milnacipran (mln) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (fm) patients. most fm trials focus primarily on pain reduction with monotherapy. polypharmacy is commonly used, but supportive evidence is limited. the gabapentin-mln combined therapy may be more effective in female patients with fm than their monotherapy.

the aim of the study is to evaluate the analgesic efficacy of gabapentin-mln as combined or monotherapy on patients with fm.

Eligibility criteria:
inclusion criteria: * there are no other criteria rather than age and sex exclusion criteria: * patient refusal. * pregnancy or breastfeeding. * active liver disease * renal impairment (creatinine clearance \< 60 ml/min). * documented autoimmune disease. * severe chronic obstructive pulmonary disease. * recent arrhythmia * myocardial infarction * stroke. * uncontrolled hypertension. * glaucoma.